University of Texas SPORE in Lung Cancer: A Collaboration Between The University of Texas Southwestern Medical Center (UTSW) and The University of Texas M. D. Anderson Cancer Center (MDACC). The strategic plan of this SPORE is to identify and understand the molecular """"""""hallmarks of lung cancer"""""""" and then translate this information into the clinic for early detection, prevention, prognosis, and the selection and/or development of new treatments for lung cancer. We have invested in several major translational research themes: identification of key lung cancer tumor suppressor genes and their development as novel therapeutics; identification of persons with an increased inherited and/or acquired risk of developing lung cancer by genetic epidemiology and early detection of respiratory epithelial genetic and epigenetic alterations; identification of abnormalities in apoptosis and invasion during lung cancer pathogenesis; understanding signaling pathways that are likely new targets for chemoprevention and therapy of lung cancer; and developing lung cancer therapies directed against telomerase. To achieve these goals, our SPORE has assembled clinicians and basic scientists including medical oncologists, thoracic surgeons, pulmonary physicians, pathologists, molecular geneticists, molecular and cell biologists, epidemiologists, behavioral and psycho-pharmacologists, biostatisticians, and experts in development of new technologies and informatics. The SPORE, brings together two major complementary strengths in lung cancer research involving UTSW and MDACC. This SPORE consists of 5 inter-related projects and 4 supporting Cores. The projects involve: 1. Translation of tumor suppressor genes into new therapeutics for lung cancer; 2. Molecular epidemiology of lung cancer: comparison of surrogate and target tissues markers; 3. Molecular pathology of lung cancer related to apoptosis and invasion and its translation into the clinic; 4.The PI3K pathway as a target for lung cancer prevention and therapy; and 5. Targeting telomerase for lung cancer therapeutics The Cores are: Administrative; Pathology & Tissue Resources; Biostatistics; and Computational Biology & Innovative Technology. All of the scientific projects are: translational in nature; focus on human lung cancer; involve clinical and basic investigators and biostatisticians; interact with the other projects; and utilize Core resources. Innovative Developmental and Career Development Projects have brought new investigators into and stimulated the SPORE that are represented in each of the major projects. We also have a developmental project dealing with new methods of smoking cessation by elucidating genetic contributions to nicotine addiction and response to pharmacological treatment of nicotine addiction. This SPORE also participates in the inter-SPORE effort of the Lung Cancer Biomarkers and Chemoprevention Consortium (LCBCC). Achievement of the aims and objectives of this proposal will result in a major decrease in the incidence, morbidity and mortality of lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA070907-07S1
Application #
6933603
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Rosenfeld, Bobby
Project Start
1996-09-30
Project End
2008-04-30
Budget Start
2004-05-01
Budget End
2005-04-30
Support Year
7
Fiscal Year
2004
Total Cost
$71,760
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Akbay, Esra A; Kim, James (2018) Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. Transl Lung Cancer Res 7:464-486
Zhang, Wei; Girard, Luc; Zhang, Yu-An et al. (2018) Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Transl Lung Cancer Res 7:32-49
Tan, Xiaochao; Banerjee, Priyam; Liu, Xin et al. (2018) The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest 128:1267-1282
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Walser, Tonya C; Jing, Zhe; Tran, Linh M et al. (2018) Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Res 78:1986-1999
Skoulidis, Ferdinandos; Goldberg, Michael E; Greenawalt, Danielle M et al. (2018) STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 8:822-835
Zhou, Xiaorong; Padanad, Mahesh S; Evers, Bret M et al. (2018) Modulation of Mutant KrasG12D -Driven Lung Tumorigenesis In Vivo by Gain or Loss of PCDH7 Function. Mol Cancer Res :
Ferdosi, Shadi; Rehder, Douglas S; Maranian, Paul et al. (2018) Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, ?1-4 Branching, ?1-6 Branching, and ?2-6 Sialylation in Cancer. J Proteome Res 17:543-558
Pietanza, M Catherine; Waqar, Saiama N; Krug, Lee M et al. (2018) Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol 36:2386-2394
Abrams, Zachary B; Zucker, Mark; Wang, Min et al. (2018) Thirty biologically interpretable clusters of transcription factors distinguish cancer type. BMC Genomics 19:738

Showing the most recent 10 out of 1059 publications